Skip to main content

Table 4 Correlations of changes in SF-36 BP, VT, and MCS scores with changes in DLQI and pruritus VAS scores at week 16

From: Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

  Placebo Apremilast BID
   10 mg 20 mg 30 mg
SF-36 BP with DLQI −0.45* −0.32* −0.52* −0.35*
P<0.001 P=0.002 P<0.001 P=0.001
SF-36 VT with DLQI 0.38* −0.18 −0.33* −0.23
P<0.001 P=NS P=0.003 P=0.040
SF-36 MCS with DLQI −0.57* −0.41* −0.42* −0.31*
P<0.001 P<0.001 P<0.001 P=0.004
SF-36 BP with pruritus VAS −0.39* −0.27 −0.43* −0.30
P<0.001 P=0.013 P<0.001 P=0.005
SF-36 VT with pruritus VAS −0.36* 0.01 −0.11 −0.23
P=0.001 P=NS P=NS P=0.034
SF-36 MCS with pruritus VAS −0.35* −0.21 −0.12 −0.35*
  P=0.001 P=NS P=NS P=0.001
  1. *Moderate correlations (r>0.30 and ≤0.60).
  2. BP, Bodily Pain; DLQI, Dermatology Life Quality Index; MCS, mental component summary; SF-36, Short-Form 36 Health Survey; VAS, visual analog scale; VT, Vitality.